Voltarra seeks 'lightning' strike with zoledronic acid derivative in knee OA
By Marie Powers
Wednesday, May 21, 2014
Launched last year with a portfolio of early stage small molecules and late-stage clinical assets assembled through a pair of acquisitions, Voltarra Pharmaceuticals Inc. has moved like lightning a strategy underpinning the company's name into phase III trials for its lead candidate.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.